Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo

NCT02505542 is registered in ClinicalTrials.gov with UCB BIOSCIENCES GmbH as lead sponsor.

NCT NCT02505542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02505542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo
Lead sponsor
UCB BIOSCIENCES GmbH
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2015
Completion date
April 30, 2019
Enrollment
736 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, axial spondyloarthrithis